A Phenomics Australia case study
Multidrug-resistant bacteria are a leading public health threat. With the help of the Phenomics Australia Histopathology and Slide Scanning Service, researchers have identified a new antibiotic to target these bacteria. The drug candidate is being tested in a clinical trial. Read the full article here.
Click here and here to know more about how Phenomics Australia is supporting the Monash Institute of Pharmaceutical Sciences in developing new generation antibiotics to treat antibiotic-resistant infections.
The challenge:
Antimicrobial resistance is a leading threat to global public health. New antibiotics are urgently needed, but there are few drugs in the development pipeline.
The solution:
With the help of the Phenomics Australia Histopathology and Slide Scanning Service at the University of Melbourne, researchers at Monash Biomedicine Discovery Institute have identified the novel antibiotic that targets multidrug-resistant bacteria.
The future:
The drug has been licensed to US biotechnology company Qpex Biopharma. A phase I clinical trial for the drug, which is now called QPX9003, began in June 2021.
References:
New antibiotic candidate to tackle deadly bacterial ‘superbugs’. Link here.
Antibiotic resistance is threatening our health. Will bacterial infection send us back to the medical dark age? Link here.
New antibiotic to combat deadly bacterial ‘superbugs’ enters clinical trials. Link here.
Monash Biomedicine Discovery Institute. Link here.
Qpex Biopharma. Link here.
Identifying a new polymyxin for antibiotic drug development. Link here.
